2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2074 IWG 2023 criteria should serve as the response endpoint for combined TP53 mutant MDS/AML trials

Elyse Olesinski, MD, MPH, Brian Do2, Brandon James Aubrey, MBBS PhD FRACP FRCPA3, Gabriela Soriano Hobbs, MD4, Rupa Narayan, MD5, Michelle Hyunju Lee, MD6, Philip Amrein, MD7, Hanno Hock8, Kamal Menghrajani, MD9, Robert Hasserjian10, Amir T. Fathi, MD11, Andrew M Brunner, MD12
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
6 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
9 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
11 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
12 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States

Background: TP53 mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are lethal myeloid malignancies with complex cytogenetics, treatment resistance, and poor overall survival (OS). Growing evidence of their molecular and prognostic similarity has driven efforts to merge them into a single TP53 mutant myeloid neoplasm. However, response criteria remain disease-specific (IWG in MDS, ELN in AML), which may hinder clinical trial accrual and drug development for a combined TP53 group. It is unknown which response framework best predicts prognosis when TP53 MDS and AML are assessed as one group and whether any retains prognostic value after allogeneic transplant (HCT). We compared the prognostic discrimination of IWG 2006, IWG 2023, and ELN 2022 criteria for OS in a combined TP53 mutant MDS/AML cohort.

Methods: We identified 112 patients with TP53 mutant MDS (n=62, <20% blasts) or AML (n=50, >20% blasts) treated at our institution with hypomethylating agents (HMA), HMA plus venetoclax (HMA-VEN), or intensive chemotherapy (IC). TP53 allele status was assigned per WHO 2022 criteria using mutation number, variant allele frequency, cytogenetics (deletion of chr17 or 17p), and copy-neutral loss of heterozygosity. Best response to first-line therapy was classified per published criteria under IWG 2006, IWG 2023, and ELN 2022 criteria; responders excluded stable disease, no response, or disease progression. The primary outcome was OS from treatment initiation and censored at HCT. Discrimination quality was quantified via Harrell’s C-index with 95% confidence intervals (CI) from 1,000 bootstrap resamples and optimism-corrected. Separate multivariate Cox models estimated the association of response with OS, adjusted for age, sex, marital status, allele status, treatment, co-mutations, and cytogenetic clearance. Sensitivity analyses modeled HCT as time-dependent, repeated OS without HCT censoring, and restricted to biallelic disease.

Results: Mean age was 66.6 years; 55.4% MDS, 44.6% AML, and 83.9% biallelic TP53. Therapy was HMA (39.3%, OS 8.56 mo), HMA-VEN (32.1%, OS 10.2 mo), or IC (25.0%, OS 4.62 mo). Median OS censored at HCT was 8.85 months (MDS 10.23 mo, AML 6.59 mo), and 39.3% underwent HCT. Response rates were 53.6% (IWG 2006), 43.8% (IWG 2023), and 51.7% (ELN 2022).

IWG frameworks separated responders from non-responders, but ELN did not. Median OS was 13.1 vs 4.5 mo for IWG 2006 (p<0.0001), 13.6 vs 5.8 mo for IWG 2023 (p=0.0001), and 11.7 vs 5.8 mo for ELN 2022 (p=0.06). IWG frameworks discriminated equivalently (C-index 0.70 vs 0.68; =0.02, p=0.50), and both exceeded ELN (0.62; p=0.04 vs IWG 2006). Response remained independently prognostic in multivariate models for IWG 2006 (p=0.0007) and IWG 2023 (p=0.0024) but not ELN 2022 (p=0.30), and findings were unchanged in biallelic-only patients (n=94).

Prognostic value was confined to pre-HCT course, as pre-HCT response did not predict post-HCT survival under any framework (initial analysis, n=44, all p>0.60). Modeling HCT as a time-dependent covariate confirmed this, with response predicting OS before but not after HCT (IWG 2006 HR 2.60 vs 0.93, p=0.04; IWG 2023 HR 2.43 vs 0.71, p=0.01; ELN 2022 HR 1.70 vs 0.99, p=0.27). Without HCT censoring, both IWG frameworks stayed prognostic (p=0.0015, p=0.0019), with differences concentrated early and consistent with post-HCT relapse. ELN was not significant uncensored (p=0.07). Finally, IWG 2023 response depth was graded: OS worsened monotonically across responder, hematological improvement (HI) only, and non-responder tiers (median OS 14.3 vs 8.5 vs 5.8 mo; per-tier HR 1.77, p=0.0005).

Conclusion: In this first head-to-head comparison of response criteria in a combined TP53 mutant MDS/AML cohort, both IWG frameworks stratified OS and remained independently prognostic. ELN 2022 did not, which likely reflects anchoring on complete remission (CR) and blast clearance. Such remissions are short-lived in TP53 disease. Prognostic value was confined to the pre-HCT course, with no framework predicting post-HCT survival. Because IWG 2006 and IWG 2023 discriminated equivalently, the choice between them rests on design rather than performance. IWG 2023 achieves the same discrimination with fewer categories and grades intermediate responses that track OS when deep remission is rare. These findings support IWG 2023 as a harmonized measure for TP53 myeloid neoplasm trials.
Elyse Olesinski, MD, MPH: No relevant conflicts of interest to declare.